Fig.1

Efficacy of cell killing by oncolytic T1012G and propranolol as separate agents and combined treatment on cell proliferation in gastric cancer cell lines. A and B CCK8 assay measured cell viability after T1012G (0.01, 0.05, 0.1, 1, 2,5 MOI) and propranolol (20, 40, 60, 80, 100,120,160 µM) treatment for 48 h. C and E The survival rate from the co-treatment of T1012G (0.01, 0.05, 0.1, 1, 2, 5 MOI) and propranolol (40, 60 µM in HGC and AGS; 60, 80 µM in MFC) at 48 h. F HGC-27 cells were seeded on 96-well plates. After 48 h of incubation with or without propranolol (40 μmol/l), cells were infected with different dose of virus (0.01, 0.05, 0.1, 0.5, 1 MOI). The number of surviving cells in each well was determined 2 days after infection. Data are presented as mean ± SEM. Significant differences were evaluated using one-way ANOVA, and the asterisk (*) indicates a significant difference compared the same T1012G dose or propranolol alone with the combination group using Games-Howell's multiple comparisons test (P < 0.05). Pro, propranolol. 40/60/80 µM → indicates the cell viability corresponding to propranolol treatment alone